InventisBio (SH:688382)2023-10-27 16:00Financial Performance - The company's operating revenue for Q3 2023 was ¥47,169,811.32, with a total revenue of ¥127,169,811.32 for the year-to-date period[5] - The net profit attributable to shareholders for Q3 2023 was -¥73,512,498.62, and -¥241,261,887.25 for the year-to-date period[5] - The basic and diluted earnings per share for Q3 2023 were both -¥0.13, with a year-to-date figure of -¥0.42[6] - Total operating revenue for the first three quarters of 2023 was CNY 127,169,811.32, compared to CNY 127,169,811.32 in the same period of 2022, indicating no growth[20] - Net profit for Q3 2023 was CNY -241,261,887.25, an improvement from CNY -385,003,047.30 in Q3 2022, showing a reduction in losses of about 37.3%[21] - Basic and diluted earnings per share for Q3 2023 were both CNY -0.42, compared to CNY -0.79 in Q3 2022, reflecting a decrease in loss per share[23] - The total comprehensive income for Q3 2023 was CNY -241,854,191.87, an improvement from CNY -386,067,242.25 in Q3 2022, reflecting a reduction in comprehensive losses of about 37.5%[22] Assets and Liabilities - The total assets at the end of Q3 2023 were ¥2,158,198,587.36, representing a decrease of 7.83% compared to the end of the previous year[6] - As of September 30, 2023, total current assets amounted to RMB 2,113,515,925.86, a decrease from RMB 2,265,470,912.30 as of December 31, 2022, reflecting a decline of approximately 6.7%[17] - The total assets of the company as of September 30, 2023, were RMB 2,158,198,587.36, down from RMB 2,341,609,014.39 at the end of 2022, indicating a decrease of about 7.8%[18] - Current liabilities totaled RMB 126,541,209.60 as of September 30, 2023, compared to RMB 111,015,225.74 at the end of 2022, representing an increase of approximately 14.0%[18] - Total liabilities as of Q3 2023 amounted to CNY 135,166,917.45, an increase from CNY 126,686,902.60 in the previous year[21] - The company experienced a decrease in equity attributable to shareholders of 8.66% compared to the end of the previous year, totaling ¥2,023,031,669.91[6] - Total equity attributable to shareholders of the parent company was CNY 2,023,031,669.91, down from CNY 2,214,922,111.79 in the same period last year, indicating a decline of approximately 8.6%[21] Cash Flow - The company reported a cash flow from operating activities of -¥234,600,234.01 for the year-to-date period[6] - Cash inflows from operating activities for the first three quarters of 2023 totaled CNY 90,660,912.61, significantly up from CNY 16,488,618.50 in the same period of 2022[25] - The net cash flow from operating activities was -$234.6 million, an improvement from -$330.7 million in the previous quarter[26] - The ending balance of cash and cash equivalents was $1.99 billion, down from $2.39 billion at the end of the previous quarter[26] Research and Development - Research and development expenses for Q3 2023 amounted to ¥111,801,241.62, a decrease of 29.34% year-over-year, and accounted for 237.02% of operating revenue[6] - Research and development expenses for Q3 2023 were CNY 349,006,011.76, compared to CNY 377,257,640.15 in Q3 2022, representing a decrease of about 7.5%[21] Operational Strategy - The company confirmed that there were no significant changes in its operational strategies or market expansion plans during the reporting period[4] - The company has not disclosed any new product launches or technological advancements during this reporting period[16] - There were no significant mergers or acquisitions reported in the latest quarter, indicating a focus on organic growth strategies[16]